Quarterly report pursuant to Section 13 or 15(d)

Investment in Macrophage Therapeutics, Inc.

v3.5.0.2
Investment in Macrophage Therapeutics, Inc.
9 Months Ended
Sep. 30, 2016
Investments In And Advances To Affiliates Schedule Of Investments [Abstract]  
Investment in Macrophage Therapeutics, Inc.

7.

Investment in Macrophage Therapeutics, Inc.

In December 2015 and May 2016, Platinum contributed a total of $200,000 to MT.  MT was not obligated to provide anything in return, although it was considered likely that the MT Board would ultimately authorize some form of compensation to Platinum.  As such, the Company recorded the $200,000 as a current liability pending determination of the form of compensation.

In July 2016, MT’s Board of Directors authorized modification of the original investments of $300,000 by Platinum and $200,000 by Dr. Goldberg to a convertible preferred stock with a 10% paid-in-kind (PIK) coupon retroactive to the time the initial investments were made.  The conversion price of the preferred will remain at the $500 million initial market cap but a full ratchet will be added to enable the adjustment of conversion price, warrant number and exercise price based on the valuation of the first institutional investment round.  In addition, the MT Board authorized issuance of additional convertible preferred stock with the same terms to Platinum as compensation for the additional $200,000 of investments made in December 2015 and May 2016.  As of the date of filing of this Form 10-Q, final documents related to the above transactions authorized by the MT Board have not been completed.